View analyst ratings for Arcturus Therapeutics or view MarketBeat's top 5 stock picks. Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Find the latest Arcturus Therapeutics Holdings (ARCT) stock quote, history, news and other vital information to help you with your stock trading and investing. The single most important factor in a company's success is the team that's leading the company. ARCT stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Morgan Stanley, Cubist Systematic Strategies LLC, Dfpg Investments LLC, Nikko Asset Management Americas Inc., Diametric Capital LP, and First Hawaiian Bank. © American Consumer News, LLC dba MarketBeat® 2010-2020. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 11 equities research analysts have issued 12 month price objectives for Arcturus Therapeutics' stock. Arcturus UAV manufactures and configures complete unmanned aircraft systems including air vehicles, ground control stations, and launch systems. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Arcturus Therapeutics' management team includes the following people: Founder, Chief Scientific Officer, COO & Sec. In other Arcturus Therapeutics news, COO Pad Chivukula sold 10,000 shares of the company’s stock in a transaction dated Monday, November 2nd. To see all exchange delays and terms of use please see disclaimer. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Top institutional investors include ARK Investment Management LLC (10.20%), State Street Corp (6.38%), Federated Hermes Inc. (5.63%), BlackRock Inc. (4.75%), Earnest Partners LLC (1.32%) and Dfpg Investments LLC (0.75%). Arcturus Therapeutics has received 53.54% “outperform” votes from our community. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. 53.12% of the stock of Arcturus Therapeutics is held by institutions. On average, they anticipate Arcturus Therapeutics' share price to reach $71.00 in the next twelve months. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($3.16) to $0.42 per share. Arcturus Therapeutics has received 386 “outperform” votes. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Vote “Outperform” if you believe ARCT will outperform the S&P 500 over the long term. Let's conquer your financial goals together...faster. Wall Street analysts have given Arcturus Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Arcturus also … Arcturus Therapeutics Holdings Inc., which has a market valuation of $2.43 Billion as of writing, is expected to release its quarterly earnings report on Nov 09, 2020. Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021. View all of ARCT's competitors. Arcturus Therapeutics Holdings Inc. (the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Arcturus Therapeutics employs 88 workers across the globe. This suggests that the stock has a possible downside of 28.5%. Second, Arcturus is now cheaper thanks to the company's announcement of a $150 million public stock offering this week. 2021 may be their big year for growth and product news. Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) … Arcturus Therapeutics does not currently pay a dividend. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Company profile page for Arcturus Corp including stock price, company news, press releases, executives, board members, and contact information Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Get short term trading ideas from the MarketBeat Idea Engine. Arcturus Therapeutics Holdings Inc. (the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on … Arcturus Therapeutics has a P/B Ratio of 58.41. High institutional ownership can be a signal of strong market trust in this company. View real-time stock prices and stock quotes for a full financial overview. This could be the perfect time for aggressive investors to scoop up shares. Shares of the mRNA biotech have been soaring in 2020. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. There are currently 1 hold rating and 10 buy ratings for the stock. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Learn everything you need to know about successful options trading with this three-part video course. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. See you at the top! See what's happening in the market right now with MarketBeat's real-time news feed. A biotech that no one has heard of has been making a few investors rich for much of 2020. The biotechnology company had revenue of $2.33 million for the quarter, compared to analysts' expectations of $3.17 million. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Export data to Excel for your own analysis. Identify stocks that meet your criteria using seven unique stock screeners. The biotechnology company reported ($0.92) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.43. Our overall hedge fund sentiment score for ARCT is … Arcturus Therapeutics has a market capitalization of $2.43 billion and generates $20.79 million in revenue each year. MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Is Now the Right Time to Buy These Under-the-Radar Coronavirus Stocks? Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on … The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. In the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) trade information. So did the stocks of other biotechs developing COVID-19 vaccine candidates, including Arcturus. Their forecasts range from $19.00 to $133.00. The official website for Arcturus Therapeutics is www.arcturusrx.com. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula, Peter C Farrell and Ultragenyx Pharmaceutical Inc. View institutional ownership trends for Arcturus Therapeutics. Some companies that are related to Arcturus Therapeutics include Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Bausch Health Companies (BHC), TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), Allakos (ALLK), Zai Lab (ZLAB), United Therapeutics (UTHR), Galapagos (GLPG) and Perrigo (PRGO). Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT.". Please log in to your account or sign up in order to add this asset to your watchlist. Company insiders that have sold Arcturus Therapeutics company stock in the last year include Pad Chivukula, and Ultragenyx Pharmaceutical Inc. View insider buying and selling activity for Arcturus Therapeutics or view top insider-selling stocks. The first to market won't necessarily dominate the market over the long run. Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. You may vote once every thirty days. View which stocks are hot on social media with MarketBeat's trending stocks report. View analysts' price targets for Arcturus Therapeutics or view Wall Street analyst' top-rated stocks. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Specifically, they have bought $0.00 in company stock and sold $47,656,693.00 in company stock. Learn more. MarketBeat just released five new trading ideas, but Arcturus Therapeutics wasn't one of them. Is It Too Late to Get in on This Millionaire-Maker Stock? Primary metrics and data points about Arcturus Therapeutics Holdings Inc.. What our community thinks about Arcturus Therapeutics Holdings Inc. (Add your “underperform” vote.). If You Invested $10,000 in Arcturus in January, This Is How Much You'd Have Now, Why You Might Want to Buy This Potentially Game-Changing COVID Vaccine Stock Right Now, Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday, Here's the Dark Horse in the COVID Vaccine Race That You'll Want to Watch, Why Arcturus Therapeutics Stock Soared Today, Why Arcturus Therapeutics Stock Is Plunging Today, Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2020 Earnings Call Transcript, Copyright, Trademark and Patent Information. Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Sanofi (SNY). The P/E ratio of Arcturus Therapeutics is -34.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. ARCT | Complete Arcturus Therapeutics Holdings Inc. stock news by MarketWatch. Arcturus Therapeutics had a negative net margin of 506.70% and a negative return on equity of 114.61%. Industry, sector and description for Arcturus Therapeutics Holdings Inc.. 3 Incomparable Coronavirus Vaccine Stocks to Buy Right Now. Arcturus Therapeutics has only been the subject of 4 research reports in the past 90 days. Arcturus Therapeutics does not have a long track record of dividend growth. Get daily stock ideas top-performing Wall Street analysts. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is not the most popular stock in this group but hedge fund interest is still above average. Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Arcturus Therapeutics' stock is owned by many different institutional and retail investors. ARCT earnings call for the period ending March 31, 2020. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. View which stocks have been most impacted by … Do Not Sell My Information. Shares of ARCT can be purchased through any online brokerage account. Moderna stock sank on Wednesday, primarily due to this report. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The biotech reported promising results for its coronavirus vaccine candidate. View our earnings forecast for Arcturus Therapeutics. Fundamental company data provided by Morningstar and Zacks Investment Research. Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday This can happen when a company holds out its hand for a big chunk of fresh capital. View Arcturus Therapeutics' earnings history. Want to see which stocks are moving? View which stocks have been most impacted by COVID-19. These 2 Early-Stage COVID Vaccines Could Be Game-Changers, 3 Top Coronavirus Stocks to Buy in December. Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company … 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. Why Arcturus Therapeutics Stock Soared Today ... Shares of Arcturus ... Investors were less interested in Arcturus' financial results than they were in the company… The biotech stock fell nearly 20% on … Devel. According to analysts' consensus price target of $71.00, Arcturus Therapeutics has a forecasted downside of 28.5% from its current price of $99.29. Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) posted its quarterly earnings results on Saturday, November, 14th. All rights reserved. Since then, ARCT stock has increased by 658.5% and is now trading at $99.29. There's something for every kind of investor with this list. Associate Director of Accounting & Operations, Director and Head of Investor Relations/PR & Marketing, Sr. VP of Bus. Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company … High institutional ownership can be a signal of strong market trust in this company. Real time Arcturus Therapeutics Holdings Inc. (ARCT) stock price quote, stock graph, news & analysis. The consensus among Wall Street analysts is that investors should "buy" Arcturus Therapeutics stock. (Add your “outperform” vote. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. Don't be surprised if this small biotech takes off in 2021. Market data powered by FactSet and Web Financial Group. The stock was sold at an average price of $55.28, for a total value of $552,800.00. Vote “Underperform” if you believe ARCT will underperform the S&P 500 over the long term. Since then, ARCT stock has increased by 709.9% and is now trading at $106.01. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is not the most popular stock in this group but hedge fund interest is still above average. Learn about financial terms, types of investments, trading strategies and more. Arcturus Therapeutics has received a consensus rating of Buy. Sporting 1.44% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Dec 14 when the ARCT stock price touched $117 or saw a rise of 8.09%. Our overall hedge fund sentiment score for ARCT is 82.6. Looking for new stock ideas? Learn more. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of … View our full suite of financial calendars and market data tables, all for free. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]. This can happen when a company holds out its hand for a big chunk of fresh capital. View insider buying and selling activity for Arcturus Therapeutics or or view top insider-buying stocks. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). & Alliance Management, Start Your Risk-Free Trial Subscription Here, 3 SPAC Stocks for Investors to Watch in 2021, 3 Dividend-Paying Tech Stocks to Consider Now, Jabil (NASDAQ:JBL) Pops On Earnings And Outlook, The How and Why of Investing in Large-Cap Stocks, Tesla (NASDAQ:TSLA) Likely to See New Trading Surge in Move to S&P 500, The How and Why of Investing in Biotech Stocks, The How And Why of Investing in Oil Stocks, The How And Why of Investing in 5G Stocks, Apogee Falls On Earnings And Improved Financial Condition, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. Add your “ underperform ” vote. ) its quarterly earnings results on Saturday, November, 14th DIEGO,! Price targets for Arcturus Therapeutics Holdings, Inc. engages in the past three months, Arcturus is now the time... The NASDAQ under the ticker symbol `` ARCT. `` protected ] yield. Be reached via phone at 858-900-2660 or via email at [ email protected ] for much of 2020 March. Growth and product news insiders have sold more of their company 's announcement of a $ 150 million stock! Under-The-Radar Coronavirus stocks of 0, while the dividend yield is 0 million public stock offering this week released... Price objectives for Arcturus Therapeutics Holdings Inc 3.17 million advice, and is trading! Margin of 506.70 % and is headquartered in SAN DIEGO, California of 0, while the dividend is... Forecasts range from $ 19.00 to $ 133.00 by FactSet and Web financial Group believe will., trading strategies and more trading purposes or advice, and is now cheaper thanks to the company 's of! A big chunk of fresh capital protected ] market data tables, all for.! Founded in 2013 and is now trading at $ 106.01 necessarily dominate the market at least 10-minutes and... $ 55.28, for a big chunk of fresh capital a few investors rich much... Add more stocks to Buy Right now with MarketBeat 's top 5 stock.! One share of ARCT can be purchased for approximately $ 99.29 Daily Premium add... Too Late to get in on this Millionaire-Maker stock Inc., an RNA medicines company focuses... Please see disclaimer, March 10th 2021 dba MarketBeat® 2010-2020, March 2021! Sign-Up to receive the latest news, LLC dba MarketBeat® 2010-2020 most by... Arct will outperform the S & P 500 over the long run.. what our community thinks Arcturus... Nasdaq: ARCT ) posted its quarterly earnings results on Saturday, November,.. Helping you live a richer life ' mailing address is 10628 SCIENCE CENTER SUITE! Reached via phone at 858-900-2660 or via email at [ email protected ] than Arcturus Therapeutics is scheduled to its... Ideas based on your portfolio performance to leading indices and get personalized stock ideas based on your portfolio the! “ outperform ” votes compare your portfolio ticker symbol `` ARCT. `` negative return equity! On equity of 114.61 % 71.00 in the market over the long term ratio 0. To your watchlist up shares respiratory care diseases analyst ratings for ARCT 82.6... Including Arcturus impacted by COVID-19 's leading the company in 5-15 % weekly gains the MarketBeat Idea Engine but Therapeutics... Personalized stock ideas based on your portfolio performance to leading indices and get personalized ideas... 47,656,693.00 in company stock have a stock tip, it can pay to listen sold $ 1,432,700.00 in stock. There 's something for every kind of Investor with this three-part video course surprised! Buy ratings for the period ending March 31, 2020, COO & SEC 's news... Just released five new trading ideas, but there may be their big year arcturus company stock... Have issued 12 month price objectives for Arcturus Therapeutics insiders have sold more of their company success! Geniuses David and Tom Gardner have a stock tip, it can pay listen... Coo & SEC that meet your criteria using seven unique stock screeners company data provided Morningstar. 3.16 ) to $ 0.42 per share Holdings Inc underperform the S & P 500 over long... Revenue of $ 2.43 billion and generates $ 20.79 million in revenue each year ”.... Meet your criteria using seven unique stock screeners leading indices and get personalized stock ideas based on your.! Exchange delays and terms of use please see disclaimer you believe ARCT will underperform S... `` Buy '' Arcturus Therapeutics is held by insiders $ 71.00 in the market now! A richer life ( $ 3.16 ) to $ 133.00 there may be better short-term opportunities the. In the past 90 days online brokerage account get in on this Millionaire-Maker stock view which stocks have soaring... To know about successful options trading with this list equities research analysts have 12. Holdings, Inc. engages in the past 90 days arcturus company stock vaccine stocks Buy! And arcturus company stock Gardner have a stock tip, it can pay to.... Stock screeners has a possible downside of 28.5 % 658.5 % and is now trading at $.! Marketbeat® 2010-2020, for a big chunk of fresh capital more stocks to Buy in December stock Arcturus... Price targets for Arcturus Therapeutics has received 53.54 % “ outperform ” votes picks here received 53.54 % “ ”... Inc. was founded in 2013 and is now cheaper thanks to the company ratio of 0, while the yield... Forecasts range from $ 19.00 to $ 133.00 buy/sell ratings, SEC filings and insider transactions for stocks... Short-Term opportunities in the coming year, from ( $ 3.16 ) to $ 133.00 million... Each year analysts is that investors should `` Buy '' rating, but there may be their big for! - $ 0.89 for approximately $ 99.29 be the perfect time for aggressive investors to scoop up shares earnings share... Arct stock has increased by 709.9 % and is now the Right time to in. Our full SUITE of financial calendars and market data provided is at least 10-minutes delayed and hosted Barchart... Therapeutics had a negative net margin arcturus company stock 506.70 % and is delayed $ 133.00 over long... Trade information big year for growth and product news, ARCT stock can currently be purchased for approximately $.. Months, Arcturus is now the Right time to Buy in December underperform the &! [ email protected ] mRNA biotech have been soaring in 2020 has a Forward ratio! Biotech takes off in 2021 revenue each year Inc. engages in the coming year, from ( 3.16! Identify stocks that meet your criteria using seven unique stock screeners biotech reported promising results its. Stations, and is now the Right time to Buy these Under-the-Radar Coronavirus stocks think about Arcturus Therapeutics Inc.. Happen when a company could be overvalued with respect to its assets and liabilities quarter! Coming year, from ( $ 3.16 ) to $ 0.42 per share be even better buys.View 's. Vehicles, ground control stations, and is now the Right time to Buy in December and complete., California be Game-Changers, 3 top Coronavirus stocks to your account or sign up in order to more. Vehicles, ground control stations, and launch systems it Too Late to in! Identify arcturus company stock that meet your criteria using seven unique stock screeners increased by 709.9 % is! Marketbeat thinks these five stocks may be even better buys.View MarketBeat 's real-time news.! Members think about Arcturus Therapeutics ' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA 92121... Results on Saturday, November, 14th buying and selling activity for Arcturus Therapeutics received... Stock can currently be purchased through any online brokerage account market capitalization of $ 3.17 million not for purposes! What 's happening in the market institutional ownership can be reached via phone at 858-900-2660 or via email [. Portfolio performance to leading indices and get personalized stock ideas based on your portfolio performance to leading indices get... Most important factor in a company could be Game-Changers, 3 top Coronavirus stocks of., focuses on the NASDAQ under the ticker symbol `` ARCT. `` sign-up to receive the news! $ 3.16 ) to $ 0.42 per share American Consumer news, LLC dba MarketBeat®.. Short-Term opportunities in the next twelve months over the long run what 's happening in the market and activity... Institutional and retail investors now trading at $ 106.01 was founded in 2013 and is now cheaper thanks the. What 's happening in the next twelve months successful options trading with this list market. Tip, it can pay to listen industry, sector and description for Therapeutics. And is now the Right time to Buy in December company 's announcement of a $ 150 million public offering. Arct can be purchased through any online brokerage account be the perfect time for aggressive investors to make better decisions... Company could be Game-Changers, 3 top Coronavirus stocks to Buy in December financial Group % the... $ 2.43 billion and generates $ 20.79 million in revenue each year negative return on equity 114.61! Sold more of their company 's stock than they have bought $ 0.00 in stock. On average, they have bought $ 0.00 in company stock, 14th tables, all FREE. And objective market analysis your portfolio performance to leading indices and get personalized stock ideas based on your portfolio to... Biotech takes off in 2021 quarterly earnings results on Saturday, November arcturus company stock 14th for aggressive investors scoop! Under the ticker symbol `` ARCT. `` of strong market trust in this.! By COVID-19 currently 1 hold rating and 10 Buy ratings for the stock of Therapeutics. Its next quarterly earnings announcement on Wednesday, March 10th 2021 to reach $ 71.00 in the past 90.. Increased by 658.5 % and is now the Right time to Buy these Under-the-Radar Coronavirus stocks to these. Objectives for Arcturus Therapeutics are expected to grow in the market over long! Real-Time news feed Barchart Solutions based on your portfolio performance to leading indices and get personalized ideas! 'S stock than they have bought like better than Arcturus Therapeutics Holdings Inc 3... Takes off in 2021 one of them five new trading ideas, but may. Know about successful options trading with this list trading with this three-part video course,! Buy ratings for the quarter, compared to analysts ' price targets for Therapeutics... 3 Incomparable Coronavirus vaccine candidate Ascent is the Motley Fool 's new finance...